scholarly journals Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer

2018 ◽  
Vol Volume 10 ◽  
pp. 4805-4815 ◽  
Author(s):  
Xiaofei Zhu ◽  
Fuqi Li ◽  
Dongchen Shi ◽  
Xiaoping Ju ◽  
Yangsen Cao ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals P-180 Health-related quality of life in patients with metastatic pancreatic cancer

2016 ◽  
Vol 27 ◽  
pp. ii53
Author(s):  
V. Picozzi ◽  
S. Narayanan ◽  
L. Kayitalire ◽  
X.H. Hu ◽  
J. Vacirca
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer

2016 ◽  
Vol 48 (1) ◽  
pp. 103-109 ◽  
Author(s):  
Vincent Picozzi ◽  
Siva Narayanan ◽  
X. Henry Hu ◽  
Jeffrey Vacirca
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multi-centre, parallel group, double-blind, randomised controlled clinical trial (MISTRAL)

2020 ◽  
Author(s):  
Kathrin Wode ◽  
Johanna Hök Nordberg ◽  
Gunver Sophia Kienle ◽  
Nils Elander ◽  
Britt-Marie Bernhardson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Advanced Pancreatic Cancer ◽  
Health Related Quality ◽  
Mistletoe Extract ◽  
Related Quality ◽  
Health Related

Abstract Background Most pancreatic cancer patients present with advanced stage at diagnosis with extremely short expected survival and few treatment options. A multimodal palliative approach is necessary for symptom relief and optimisation of health-related quality of life. In a recent open-label trial of mistletoe extract for advanced pancreatic cancer patients not eligible for chemotherapy, promising results on improved overall survival and better health-related quality of life were reported. The objective of the present study is to assess the value of mistletoe extract as a complement to standard 18 treatment (palliative chemotherapy or best supportive care) in advanced pancreatic cancer patients with 19 regard to overall survival and health-related quality of life. Methods The trial is prospective, randomised, double-blind, multicentre, parallel group and placebo-controlled. In total 290 participants are randomly assigned to placebo or mistletoe extract given subcutaneously in increasing dosage from 0.01mg to 20mg three times per week for nine months. Stratification is performed for site and palliative chemotherapy. Main inclusion criteria are advanced pancreatic cancer and Eastern Cooperative Oncology Group performance status zero to two; main exclusion criteria are life expectancy less than four weeks and neuroendocrine tumour of the pancreas. Two ancillary studies on sub-sets of participants are nested in the trial: a biomarker study collecting blood samples and a cross-sectional qualitative study with semi-structured face-to-face interviews. Discussion To our knowledge, this is the first placebo-controlled randomised trial assessing the impact of mistletoe extract as a complement to standard treatment on overall survival and health-related quality of life in patients with advanced pancreatic cancer. The presented trial with its two nested ancillary studies exploring biomarkers and patient experiences is expected to give new insights into the treatment of advanced pancreatic cancer. Trial registration EU Clinical Trial Register, EudraCT Number 2014-004552-64. Registered 19 January 2016, https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004552-64/SE

Sign in / Sign up

Export Citation Format

Share Document